← Back to Search

NMDA receptor antagonist

Memantine for Germ Cell Tumors

Phase 2
Waitlist Available
Led By Heather M. Conklin, PhD
Research Sponsored by St. Jude Children's Research Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from start of memantine/placebo therapy through end of therapy (up to 12 weeks later)
Awards & highlights

Study Summary

This trial is studying how well memantine works in preventing cognitive problems in children with brain tumors who are undergoing radiation therapy.

Eligible Conditions
  • Germ Cell Tumors
  • Ependymoma
  • Brain Tumor
  • Craniopharyngioma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from start of memantine/placebo therapy through end of therapy (up to 12 weeks later)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from start of memantine/placebo therapy through end of therapy (up to 12 weeks later) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent of approached participants who consent to study participation
Percent of participants who complete all 12 weeks of memantine/placebo therapy
Percent of participants who complete at least 3 of 4 cognitive assessments
Secondary outcome measures
Change in neurobehavioral outcome
Frequency of memantine side effects

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: MemantineActive Control2 Interventions
Beginning at least two weeks prior to radiation therapy, participants receive memantine. Treatment continues for 12 weeks with periodic cognitive assessments and lab work.
Group II: PlaceboPlacebo Group2 Interventions
Beginning at least two weeks prior to radiation therapy, participants receive a placebo. Treatment and assessment are identical to the memantine group.

Find a Location

Who is running the clinical trial?

St. Jude Children's Research HospitalLead Sponsor
428 Previous Clinical Trials
5,306,579 Total Patients Enrolled
2 Trials studying Germ Cell Tumors
63 Patients Enrolled for Germ Cell Tumors
National Cancer Institute (NCI)NIH
13,667 Previous Clinical Trials
40,926,132 Total Patients Enrolled
6 Trials studying Germ Cell Tumors
3,806 Patients Enrolled for Germ Cell Tumors
Heather M. Conklin, PhDPrincipal InvestigatorSt. Jude Children's Research Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does age limit eligibility for participation in this research?

"This trial is seeking participants aged 6 to 21, and there are currently 155 clinical trials for younger patients and 408 for older adults."

Answered by AI

Are there any available opportunities for patients to take part in this trial?

"At this moment, enrollment for this particular trial is closed. The trail was first posted on November 7th 2017 and recently updated on October 21st 2022. If you are searching for alternatives, there are presently 508 studies recruiting patients with craniopharyngioma and 25 involving memantine that need volunteers."

Answered by AI

Has Memantine been certified by the FDA?

"The safety rating for memantine on the Power team's scale stands at 2, due to there being some evidence of its security but none yet regarding efficacy."

Answered by AI

To what extent is the patient cohort engaged in this research?

"This medical trial is not presently recruiting. It was initially uploaded to clinicaltrials.gov on November 7th 2017, and the listing has since been updated as recently as October 21st 2022. Thankfully, there are 508 active studies seeking patients with craniopharyngioma and 25 trials looking for volunteers taking Memantine at this time."

Answered by AI

Are there any preceding reviews or experiments that utilized Memantine?

"Currently, there are 25 Memantine clinical trials in operation with 11 of them being Phase 3. Columbus Ohio is the primary location for these trials, but 294 other sites across the globe also have active studies."

Answered by AI

To whom is this experimental research available?

"Patients with craniopharyngioma aged between 6 and 21 can apply to participate in this trial, which has a total capacity of 50 individuals."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
2017. "Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03194906.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top